Roche pushes a novel myeloma target
The company will be the first to take a FcRH5-targeting project into phase 3.
What now for NK-cell engagers?
Big pharma interest remains, but the mood is fast turning gloomy.
In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Lilly moves to overtake Relay
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
Daiichi makes its sting move
The recently unveiled conjugate DS3610a is to start phase 1.
Chia Tai keeps the TGF-β faith
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
Genmab takes its Profound buy into endometrial
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
Zymeworks restocks its clinical pipeline
After ZW171's exit, ZW251 enters the clinic.
Merus's next shot is colorectal cancer
Petosemtamab's phase 2 data in this setting should come by the year end.
